Evidence map›Paper›PMID 37587260›Full record

ArticleLeukemia2023

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.

Theresa Eifert, Chen-Jen Hsu, Alicia L Becker, Sarah Graessle, Arik Horne, Franziska Bemmann, Qirui Zhang, Michael Heuser, Valeri Vasioukhin, Sebastian Scholl and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Theresa EifertInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Chen-Jen HsuInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Alicia L BeckerInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Sarah GraessleCharité-Universitätsmedizin, 10117, Berlin, Germany.ORCID http://orcid.org/0000-0002-5260-6392
Arik HorneCharité-Universitätsmedizin, 10117, Berlin, Germany.ORCID http://orcid.org/0000-0002-4209-4573
Franziska BemmannCharité-Universitätsmedizin, 10117, Berlin, Germany.ORCID http://orcid.org/0009-0007-0533-7138
Qirui ZhangInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Michael HeuserHematology, Oncology, Hemostaseology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.ORCID http://orcid.org/0000-0001-5318-9044
Valeri VasioukhinDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sebastian SchollInnere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Andreas HochhausInnere Medizin II, Universitätsklinikum Jena, Jena, Germany.ORCID http://orcid.org/0000-0003-0626-0834
Florian SiegeristInstitute of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany.
Nicole EndlichInstitute of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany.
Lars BullingerCharité-Universitätsmedizin, 10117, Berlin, Germany.
Steven W LaneQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-8050-6209
Simon HaasCharité-Universitätsmedizin, 10117, Berlin, Germany.
Tina M SchnoederInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Florian H HeidelInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany. heidel.florian@mh-hannover.de.ORCID http://orcid.org/0000-0003-2438-1955
Universitätsmedizin Greifswald · DEGerman Cancer Research Center · DEJena University Hospital · DEMax Delbrück Center · DECharité - Universitätsmedizin Berlin · DEFred Hutch Cancer Center · USMedizinische Hochschule Hannover · DEThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scribble complex proteins can influence cell fate decisions and self-renewal capacity of hematopoietic cells. While specific cellular functions of Scribble complex members are conserved in mammalian hematopoiesis, they appear to be highly context dependent. Using CRISPR/Cas9-based genetic screening, we have identified Scribble complex-related liabilities in AML including LLGL1. Despite its reported suppressive function in HSC self-renewal, inactivation of LLGL1 in AML confirms its relevant role for proliferative capacity and development of AML. Its function was conserved in human and murine models of AML and across various genetic backgrounds. Inactivation of LLGL1 results in loss of stemness-associated gene-expression including HoxA-genes and induces a GMP-like phenotype in the leukemia stem cell compartment. Re-expression of HoxA9 facilitates functional and phenotypic rescue. Collectively, these data establish LLGL1 as a specific dependency and putative target in AML and emphasizes its cell-type specific functions.

Indexed as

Cytoskeletal ProteinsHematopoietic Stem CellsLeukemia, Myeloid, AcuteAnimalsCell DifferentiationHematopoiesisHumansMiceCytoskeletal ProteinsLLGL1 protein, human

Identifiers

PMID37587260
PMCPMC10539176
OpenAlexW4385877176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.